Collectively, these data suggest that the therapeutic targeting of MLL1- and KMT2D/MLL4-directed H3K4 methylation may be beneficial HR+, PIK3CA-mutated, breast cancer. The gene discussed is KMT2A; the disease is breast carcinoma.